EXPEDITED REVIEW
Pathology of Drug-Eluting Stents in Humans
Delayed Healing and Late Thrombotic Risk
Michael Joner, MD*,1,
Aloke V. Finn, MD ,1,
Andrew Farb, MD ,
Erik K. Mont, MD ,
Frank D. Kolodgie, PhD*,
Elena Ladich, MD*,
Robert Kutys, MS*,
Kristi Skorija, BS*,
Herman K. Gold, MD and
Renu Virmani, MD*,*
* CVPath, International Registry of Pathology, Gaithersburg, Maryland
Cardiac Unit, Department of Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts
Miami Dade County Medical Examiner Department, Heart Radiology, Miami, Florida
Interventional Cardiology Devices Branch, U.S. Food and Drug Administration, Rockville, Maryland
Manuscript received January 26, 2006;
revised manuscript received March 10, 2006,
accepted March 16, 2006.
* Reprint requests and correspondence: Dr. Renu Virmani, CVPath, International Registry of Pathology, 19 Firstfield Road, Gaithersburg, Maryland 20878 (Email: rvirmani{at}cvpath.org).
OBJECTIVES: This study examined human drug-eluting stents (DES) to determine the long-term effects of these stents on coronary arterial healing and identified mechanisms underlying late stent thrombosis (LST).
BACKGROUND: Although DES reduce the need for repeat revascularization compared with bare-metal stents (BMS), data suggest the window of thrombotic risk for Cypher (Cordis Corp., Miami Lakes, Florida) and Taxus (Boston Scientific Corp., Natick, Massachusetts) DES extends far beyond that for BMS.
METHODS: From a registry of 40 autopsies of DES (68 stents), 23 DES cases of >30 days duration were compared with 25 matched autopsies of BMS implantation. Late stent thrombosis was defined as an acute thrombus within a stent >30 days old.
RESULTS: Of 23 patients with DES >30 days old, 14 had evidence of LST. Cypher and Taxus DES showed greater delayed healing characterized by persistent fibrin deposition (fibrin score 2.3 ± 1.1 vs. 0.9 ± 0.8, p = 0.0001) and poorer endothelialization (55.8 ± 26.5%) compared with BMS (89.8 ± 20.9, p = 0.0001). Moreover, DES with LST showed more delayed healing compared with patent DES. In 5 of 14 patients suffering LST, antiplatelet therapy had been withdrawn. Additional procedural and pathologic risk factors for LST were: 1) local hypersensitivity reaction; 2) ostial and/or bifurcation stenting; 3) malapposition/incomplete apposition; 4) restenosis; and 5) strut penetration into a necrotic core.
CONCLUSIONS: The Cypher and Taxus DES result in delayed arterial healing when compared with BMS of similar implant duration. The cause of DES LST is multifactorial with delayed healing in combination with other clinical and procedural risk factors playing a role.
|
Abbreviations and Acronyms
| | BMS = bare-metal stents | | DES = drug-eluting stents | | FDA = Food and Drug Administration | | LST = late stent thrombosis |
|
This article has been cited by other articles:

|
 |

|
 |
 
R. J. Shemin
Coronary Artery Bypass Grafting Versus Stenting for Unprotected Left Main Coronary Artery Disease: Where Lies the Body of Proof?
Circulation,
December 2, 2008;
118(23):
2326 - 2329.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Adriaenssens, R. A. Byrne, A. Dibra, R. Iijima, J. Mehilli, O. Bruskina, A. Schomig, and A. Kastrati
Culotte stenting technique in coronary bifurcation disease: angiographic follow-up using dedicated quantitative coronary angiographic analysis and 12-month clinical outcomes
Eur. Heart J.,
December 1, 2008;
29(23):
2868 - 2876.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Authors/writing members, J. Daemen, M. L. Simoons, W. Wijns, A. Bagust, G. Bos, J. M. Bowen, E. Braunwald, E. Camenzind, B. Chevalier, et al.
Meeting Report * ESC Forum on Drug Eluting Stents * European Heart House, Nice, 27-28 September 2007
Eur. Heart J.,
November 26, 2008;
(2008)
ehn510v1.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Pfisterer, H. P. Brunner-La Rocca, P. Rickenbacher, P. Hunziker, C. Mueller, F. Nietlispach, G. Leibundgut, F. Bader, C. Kaiser, and for the BASKET Investigators
Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET
Eur. Heart J.,
November 25, 2008;
(2008)
ehn516v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Joner, K. Morimoto, H. Kasukawa, K. Steigerwald, S. Merl, G. Nakazawa, M. C. John, A. V. Finn, E. Acampado, F. D. Kolodgie, et al.
Site-Specific Targeting of Nanoparticle Prednisolone Reduces In-Stent Restenosis in a Rabbit Model of Established Atheroma
Arterioscler. Thromb. Vasc. Biol.,
November 1, 2008;
28(11):
1960 - 1966.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. John, R. Wessely, A. Kastrati, A. Schomig, M. Joner, M. Uchihashi, J. Crimins, S. Lajoie, F. D. Kolodgie, H. K. Gold, et al.
Differential Healing Responses in Polymer- and Nonpolymer-Based Sirolimus-Eluting Stents
J. Am. Coll. Cardiol. Intv.,
October 1, 2008;
1(5):
535 - 544.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Kukreja, Y. Onuma, H. Garcia-Garcia, J. Daemen, R. van Domburg, and P. W. Serruys
Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Long-Term Outcome After Bare Metal and Drug-Eluting Stent Implantation
Circ Cardiovasc Intervent,
October 1, 2008;
1(2):
103 - 110.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Wenaweser, J. Daemen, M. Zwahlen, R. van Domburg, P. Juni, S. Vaina, G. Hellige, K. Tsuchida, C. Morger, E. Boersma, et al.
Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice: 4-Year Results From a Large 2-Institutional Cohort Study
J. Am. Coll. Cardiol.,
September 30, 2008;
52(14):
1134 - 1140.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Lin and B. P. Helmke
Micropatterned Structural Control Suppresses Mechanotaxis of Endothelial Cells
Biophys. J.,
September 15, 2008;
95(6):
3066 - 3078.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. Pfisterer
Late Stent Thrombosis After Drug-Eluting Stent Implantation for Acute Myocardial Infarction: A New Red Flag Is Raised
Circulation,
September 9, 2008;
118(11):
1117 - 1119.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kelbaek, L. Thuesen, S. Helqvist, P. Clemmensen, L. Klovgaard, A. Kaltoft, B. Andersen, H. Thuesen, T. Engstrom, H. E. Botker, et al.
Drug-Eluting Versus Bare Metal Stents in Patients With ST-Segment-Elevation Myocardial Infarction: Eight-Month Follow-Up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) Trial
Circulation,
September 9, 2008;
118(11):
1155 - 1162.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Nakazawa, A. V. Finn, M. Joner, E. Ladich, R. Kutys, E. K. Mont, H. K. Gold, A. P. Burke, F. D. Kolodgie, and R. Virmani
Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients: An Autopsy Study
Circulation,
September 9, 2008;
118(11):
1138 - 1145.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Yau, P. Molnar, M. C. Moon, S. Buhay, J. P. Werner, K. Molnar, L. Saward, D. Del Rizzo, and P. Zahradka
meta-Iodobenzylguanidine, an Inhibitor of Arginine-Dependent Mono(ADP-ribosyl)ation, Prevents Neointimal Hyperplasia
J. Pharmacol. Exp. Ther.,
September 1, 2008;
326(3):
717 - 724.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O C Raffel, T Akasaka, and I-K Jang
Cardiac optical coherence tomography
Heart,
September 1, 2008;
94(9):
1200 - 1210.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Stettler, S. Allemann, S. Wandel, A. Kastrati, M. C. Morice, A. Schomig, M. E Pfisterer, G. W Stone, M. B Leon, J. S. d. Lezo, et al.
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis
BMJ,
August 29, 2008;
337(aug29_3):
a1331 - a1331.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Mehilli, R. A. Byrne, A. Wieczorek, R. Iijima, S. Schulz, O. Bruskina, J. Pache, R. Wessely, A. Schomig, A. Kastrati, et al.
Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis
Eur. Heart J.,
August 2, 2008;
29(16):
1975 - 1982.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Abbott
Revealing the Silver and Red Lining in Drug-Eluting Stents With Angioscopy
Circ Cardiovasc Intervent,
August 1, 2008;
1(1):
7 - 9.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Takano, M. Yamamoto, D. Murakami, S. Inami, K. Okamatsu, K. Seimiya, T. Ohba, Y. Seino, and K. Mizuno
Lack of Association Between Large Angiographic Late Loss and Low Risk of In-Stent Thrombus: Angioscopic Comparison Between Paclitaxel- and Sirolimus-Eluting Stents
Circ Cardiovasc Intervent,
August 1, 2008;
1(1):
20 - 27.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Shinke, J. Li, J. P. Chen, L. Pendyala, T. Goodchild, R. Jabara, S. Geva, T. Ueno, N. Chronos, K. Robinson, et al.
High Incidence of Intramural Thrombus After Overlapping Paclitaxel-Eluting Stent Implantation: Angioscopic and Histopathologic Analysis in Porcine Coronary Arteries
Circ Cardiovasc Intervent,
August 1, 2008;
1(1):
28 - 35.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. T. Newsome, M. A. Kutcher, and R. L. Royster
Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention
Anesth. Analg.,
August 1, 2008;
107(2):
552 - 569.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. T. Newsome, R. S. Weller, J. C. Gerancher, M. A. Kutcher, and R. L. Royster
Coronary Artery Stents: II. Perioperative Considerations and Management
Anesth. Analg.,
August 1, 2008;
107(2):
570 - 590.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Joner, G. Nakazawa, A. V. Finn, S. C. Quee, L. Coleman, E. Acampado, P. S. Wilson, K. Skorija, Q. Cheng, X. Xu, et al.
Endothelial Cell Recovery Between Comparator Polymer-Based Drug-Eluting Stents
J. Am. Coll. Cardiol.,
July 29, 2008;
52(5):
333 - 342.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Alfonso
The "vulnerable" stent why so dreadful?
J. Am. Coll. Cardiol.,
June 24, 2008;
51(25):
2403 - 2406.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Sullivan and N. Amarshi
Dual antiplatelet therapy with clopidogrel and aspirin
Am. J. Health Syst. Pharm.,
June 15, 2008;
65(12):
1134 - 1143.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Brar, J. Kim, S. K. Brar, R. Zadegan, M. Ree, I.-L. A. Liu, P. Mansukhani, V. Aharonian, R. Hyett, and A. Y.-J. Shen
Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions.
J. Am. Coll. Cardiol.,
June 10, 2008;
51(23):
2220 - 2227.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-H. Choi, A. Prasad, and S. Tsimikas
The evolution of thienopyridine therapy clopidogrel duration, diabetes, and drug-eluting stents.
J. Am. Coll. Cardiol.,
June 10, 2008;
51(23):
2228 - 2229.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. I. Hamilos, M. Ostojic, B. Beleslin, D. Sagic, L. Mangovski, S. Stojkovic, M. Nedeljkovic, D. Orlic, B. Milosavljevic, D. Topic, et al.
Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion.
J. Am. Coll. Cardiol.,
June 3, 2008;
51(22):
2123 - 2129.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. H. Shishehbor, R. Amini, L. P.J. Oliveria, I. M. Singh, P. Kelly, D. L. Bhatt, S. R. Kapadia, S. G. Ellis, P. L. Whitlow, and S. J. Brener
Comparison of Drug-Eluting Stents Versus Bare-Metal Stents for Treating ST-Segment Elevation Myocardial Infarction
J. Am. Coll. Cardiol. Intv.,
June 1, 2008;
1(3):
227 - 232.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. S. Rihal
Drug-Eluting Stents for ST-Segment Elevation Myocardial Infarction: Treatment of Choice or Is Discretion the Better Part of Valor?
J. Am. Coll. Cardiol. Intv.,
June 1, 2008;
1(3):
233 - 235.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Barilli, R. Visigalli, R. Sala, G. C. Gazzola, A. Parolari, E. Tremoli, S. Bonomini, A. Simon, E. I. Closs, V. Dall'Asta, et al.
In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function
Cardiovasc Res,
June 1, 2008;
78(3):
563 - 571.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kelbaek, L. Klovgaard, S. Helqvist, J. F. Lassen, L. R. Krusell, T. Engstrom, H. E. Botker, E. Jorgensen, K. Saunamaki, S. Aljabbari, et al.
Long-Term Outcome in Patients Treated With Sirolimus-Eluting Stents in Complex Coronary Artery Lesions: 3-Year Results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) Trial
J. Am. Coll. Cardiol.,
May 27, 2008;
51(21):
2011 - 2016.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. H Bhatt and T. H Hauser
Very Late Stent Thrombosis After Dual Antiplatelet Therapy Discontinuation in a Patient with a History of Acute Stent Thrombosis
Ann. Pharmacother.,
May 1, 2008;
42(5):
708 - 712.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. W. Krucoff, D. J. Kereiakes, J. L. Petersen, R. Mehran, V. Hasselblad, A. J. Lansky, P. J. Fitzgerald, J. Garg, M. A. Turco, C. A. Simonton III, et al.
A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
J. Am. Coll. Cardiol.,
April 22, 2008;
51(16):
1543 - 1552.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Suzuki, F. Ikeno, T. Koizumi, F. Tio, A. C. Yeung, P. G. Yock, P. J. Fitzgerald, and W. F. Fearon
In Vivo Comparison Between Optical Coherence Tomography and Intravascular Ultrasound for Detecting Small Degrees of In-Stent Neointima After Stent Implantation
J. Am. Coll. Cardiol. Intv.,
April 1, 2008;
1(2):
168 - 173.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. L. van der Hoeven, S.-S. Liem, J. Dijkstra, S. C. Bergheanu, H. Putter, M. L. Antoni, D. E. Atsma, M. Bootsma, K. Zeppenfeld, J. W. Jukema, et al.
Stent Malapposition After Sirolimus-Eluting and Bare-Metal Stent Implantation in Patients with ST-Segment Elevation Myocardial Infarction: Acute and 9-Month Intravascular Ultrasound Results of the MISSION! Intervention Study
J. Am. Coll. Cardiol. Intv.,
April 1, 2008;
1(2):
192 - 201.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. L. Pinto Slottow and R. Waksman
Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel Meeting on the Endeavor Zotarolimus-Eluting Coronary Stent
Circulation,
March 25, 2008;
117(12):
1603 - 1608.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Nakazawa, Q. Cheng, X. Xu, A. V. Finn, F. D. Kolodgie, and R. Virmani
Drug-eluting stent implantation may not affect vasomotor function in early phase.
J. Am. Coll. Cardiol.,
March 18, 2008;
51(11):
1124 - 1125.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. P. Taggart, S. Kaul, W. E. Boden, T. B. Ferguson Jr, R. A. Guyton, M. J. Mack, P. T. Sergeant, R. J. Shemin, P. K. Smith, and S. Yusuf
Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery.
J. Am. Coll. Cardiol.,
March 4, 2008;
51(9):
885 - 892.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B.-K. Koo, K.-W. Park, H.-J. Kang, Y.-S. Cho, W.-Y. Chung, T.-J. Youn, I.-H. Chae, D.-J. Choi, S.-J. Tahk, B.-H. Oh, et al.
Physiological evaluation of the provisional side-branch intervention strategy for bifurcation lesions using fractional flow reserve
Eur. Heart J.,
March 2, 2008;
29(6):
726 - 732.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. P. Taggart
Does prior PCI increase the risk of subsequent CABG?
Eur. Heart J.,
March 1, 2008;
29(5):
573 - 575.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Colombo and A. Latib
Late incomplete stent apposition after drug-eluting stent implantation: a true risk factor or "an innocent bystander"?
Heart,
March 1, 2008;
94(3):
253 - 254.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R Hoffmann, M-C Morice, J W Moses, P J Fitzgerald, L Mauri, G Breithardt, J Schofer, P W Serruys, H-P Stoll, and M B Leon
Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials
Heart,
March 1, 2008;
94(3):
322 - 328.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Ortolani, M. Balducelli, P. Marzaroli, G. Piovaccari, A. Menozzi, V. Guiducci, P. Sangiorgio, F. Tarantino, G. Geraci, F. Castriota, et al.
Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary Lesions: Results From a Real-World Multicenter Registry
Circulation,
February 19, 2008;
117(7):
923 - 930.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. L. van der Hoeven, S.-S. Liem, J. W. Jukema, N. Suraphakdee, H. Putter, J. Dijkstra, D. E. Atsma, M. Bootsma, K. Zeppenfeld, P. V. Oemrawsingh, et al.
Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study.
J. Am. Coll. Cardiol.,
February 12, 2008;
51(6):
618 - 626.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Saia, A. Marzocchi, and A. Branzi
Review: The safety of drug-eluting stents
Therapeutic Advances in Cardiovascular Disease,
February 1, 2008;
2(1):
43 - 52.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Aoki, A. Kirtane, M. B. Leon, and G. Dangas
Coronary Artery Aneurysms After Drug-Eluting Stent Implantation
J. Am. Coll. Cardiol. Intv.,
February 1, 2008;
1(1):
14 - 21.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Brasen, O. Leppanen, M. Inkala, T. Heikura, M. Levin, F. Ahrens, J. Rutanen, H. Pietsch, D. Bergqvist, A.-L. Levonen, et al.
Extracellular Superoxide Dismutase Accelerates Endothelial Recovery and Inhibits In-Stent Restenosis in Stented Atherosclerotic Watanabe Heritable Hyperlipidemic Rabbit Aorta
J. Am. Coll. Cardiol.,
December 4, 2007;
50(23):
2249 - 2253.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Takano, M. Yamamoto, Y. Xie, D. Murakami, S. Inami, K. Okamatsu, K. Seimiya, T. Ohba, Y. Seino, and K. Mizuno
Serial long-term evaluation of neointimal stent coverage and thrombus after sirolimus-eluting stent implantation by use of coronary angioscopy
Heart,
December 1, 2007;
93(12):
1533 - 1536.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Egashira, K. Nakano, K. Ohtani, K. Funakoshi, G. Zhao, Y. Ihara, J.-i. Koga, S. Kimura, R. Tominaga, and K. Sunagawa
Local Delivery of Anti-Monocyte Chemoattractant Protein-1 by Gene-Eluting Stents Attenuates In-Stent Stenosis in Rabbits and Monkeys
Arterioscler. Thromb. Vasc. Biol.,
December 1, 2007;
27(12):
2563 - 2568.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. V. Finn, M. C. John, H. K. Gold, J. Newell, G. Nakazawa, M. Joner, F. D. Kolodgie, and R. Virmani
Response to Letter Regarding Article, "Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization"
Circulation,
November 27, 2007;
116(22):
e550 - e550.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Doyle, C. S. Rihal, C. J. O'Sullivan, R. J. Lennon, H. J. Wiste, M. Bell, J. Bresnahan, and D. R. Holmes Jr
Outcomes of Stent Thrombosis and Restenosis During Extended Follow-Up of Patients Treated With Bare-Metal Coronary Stents
Circulation,
November 20, 2007;
116(21):
2391 - 2398.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|